Imetit

Imetit

SCHEMBL2895693

N=C(N)SCCc1c[nH]cn1

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 5/20 0.49
NPSR1 Q6W5P4 3/20 0.49
HRH3 Q9Y5N1 3/20 0.49
CYP2D6 P10635 3/20 0.49
ADRA2A P08913 2/20 0.49
CYP3A4 P08684 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
MEN1 O00255 1/20 0.49
THPO P40225 1/20 0.49
KMT2A Q03164 1/20 0.49
NOS1 P29475 7/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
HIF1A Q16665 1/20 0.47
BLM P54132 1/20 0.46
NOS3 P29474 3/20 0.43
NOS2 P35228 3/20 0.43
LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Imetit SCHEMBL7974417 0.98 HRH4 (0.50) HRH4NPSR1HRH3CYP2D6ADRA2A
Imetit SCHEMBL31157603 0.98 HRH4 (0.50) HRH4NPSR1HRH3CYP2D6ADRA2A
SCHEMBL27550976 0.90 HRH4 (0.51) HRH4NPSR1HRH3CYP2D6ADRA2A
SCHEMBL31157604 0.79
Histamine SCHEMBL27489895 0.77 HRH4 (0.34) HRH4HRH3TDP1TSHRCYP2C19
SCHEMBL2893700 0.74 SPHK2 (0.31) LMNA
Histamine SCHEMBL4234179 0.74 HRH4 (0.39) HRH4HRH3TDP1LMNATSHR
Histamine SCHEMBL28543874 0.74 HRH4 (0.39) HRH4HRH3TDP1LMNATSHR
Histamine SCHEMBL1668636 0.73 HRH4 (0.42) HRH4HRH3TDP1LMNATSHR
Histamine SCHEMBL5447892 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240269123-A1 MUSCLE REGENERATION PROMOTER SATO PHARMACEUTICAL CO., LTD. (JP) 2024-08-15 US claimed
US-20100137391-A1 Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder MSD K.K. (JP) 2010-06-03 US claimed
EP-1938838-A1 HISTAMINE H3 AGONIST FOR USE AS THERAPEUTIC AGENT FOR LIPID/GLUCOSE METABOLIC DISORDER BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-02 EP claimed
EP-0573542-A1 IMIDAZOLE-DERIVATIVES HAVING AGONISTIC OR ANTAGONISTIC ACTIVITY ON THE HISTAMINE H 3?-RECEPTOR. SEED CAPITAL INVESTMENTS (NL) 1993-12-15 EP claimed
WO-1992015567-A1 IMIDAZOLE-DERIVATIVES HAVING AGONISTIC OR ANTAGONISTIC ACTIVITY ON THE HISTAMINE H3-RECEPTOR SEED CAPITAL INVESTMENT (SCI) B.V. (NL) 1992-09-17 WO claimed
US-20240269123-A1 MUSCLE REGENERATION PROMOTER SATO PHARMACEUTICAL CO., LTD. (JP) 2024-08-15 US disclosed
WO-2022255250-A1 MUSCLE REGENERATION PROMOTER 佐藤製薬株式会社 2022-12-08 WO disclosed
US-9034798-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2015-05-19 US disclosed
US-8569481-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions PHARMACEUTICALS, INC. (US) 2013-10-29 US disclosed
US-20110118136-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions KOESTER HUBERT 2011-05-19 US disclosed
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-11-25 US disclosed
US-20100248264-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-09-30 US disclosed
US-20100137391-A1 Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder MSD K.K. (JP) 2010-06-03 US disclosed
EP-1938838-A1 HISTAMINE H3 AGONIST FOR USE AS THERAPEUTIC AGENT FOR LIPID/GLUCOSE METABOLIC DISORDER BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-02 EP disclosed
US-5837718-A ANTIHISTAMINES SEED CAPITAL INVESTMENT (SCI) B.V. (NL) 1998-11-17 US disclosed
EP-0573542-A1 IMIDAZOLE-DERIVATIVES HAVING AGONISTIC OR ANTAGONISTIC ACTIVITY ON THE HISTAMINE H 3?-RECEPTOR. SEED CAPITAL INVESTMENTS (NL) 1993-12-15 EP disclosed
WO-1992015567-A1 IMIDAZOLE-DERIVATIVES HAVING AGONISTIC OR ANTAGONISTIC ACTIVITY ON THE HISTAMINE H3-RECEPTOR SEED CAPITAL INVESTMENT (SCI) B.V. (NL) 1992-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118136-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions PTMS, QPCTL, SRMS HRH4 4303/4885NPSR1 2055/4885HRH3 4238/4885
US-20100137391-A1 Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder GPR119, HRH3, HRH4 HRH4 3/4885NPSR1 598/4885HRH3 2/4885
US-20240269123-A1 MUSCLE REGENERATION PROMOTER MUSK, HRH3, HGF HRH4 7/4885NPSR1 1464/4885HRH3 2/4885
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CHLSN, PTMS, SRMS HRH4 4411/4885NPSR1 3486/4885HRH3 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.